

INSTITUTIONAL BIOSAFETY COMMITTEE REVIEW

MEETING MINUTES

Meeting Date: Wednesday, March 25, 2026
Time: 9:00 am Eastern Time
Location: Zoom Teleconference
Institution: Retina Group of New England, PC, Waterford, CT
Principal Investigator: Nauman A. Chaudhry MD, FACS
Protocol: Adverum Biotechnologies, ADVM-022-13
NCT Number: NCT07482176
Meeting Type: Initial Review of Protocol and Site
Title: A Multi-Center, Randomized, Double-Masked, Active-Comparator-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of ixoberogene soroparvovec (Ixo-vec) in Participants with Neovascular Age-Related Macular Degeneration (AQUARIUS)

1. Call to order:

The Meeting was called to order at 8:59 am Eastern Time.

2. Introductions and orientation:

Introductions were made and the Chair oriented members to the meeting procedures.

3. Declaration of quorum:

Three voting members were present, including one local member unaffiliated with the institution. Also present were two Institutional Representatives and IBC Services staff. The Chair declared that a quorum was present.

4. Conflict of Interest:

The Chair requested that voting members report any conflict of interest regarding this meeting. No conflicts of interest were reported.

5. Public posting:

An Institutional Representative confirmed that notice of the meeting was publicly posted. No public comments were received by the site or the Committee regarding this review.

6. Review of proposed research:

The Chair provided an overview of the protocol.

The Chair provided an overview of the biosafety risk assessment for the protocol.

7. Determination for biosafety level and period of IBC oversight:

The Committee determined that **BSL-1 containment facilities and practices plus Standard Precautions** are required for ADVM-022, since it consists of an AAV vector administered by injection in a clinical setting.

The Committee determined that IBC oversight will continue for **3 months after the last subject's last dose of ADVM-022 locally**, provided that other biosafety criteria for study closure are also met.

8. Vote on the Protocol:

The Committee voted for the following determination on the Protocol:

X	APPROVED
	CONDITIONALLY APPROVED
	TABLED
	DISAPPROVED

DETERMINATION VOTE - YES: 3

NO: 0

ABSTAIN: 0

9. Review of Principal Investigator qualifications:

The Committee reviewed and accepted the qualifications of the Principal Investigator.

INSTITUTIONAL BIOSAFETY COMMITTEE REVIEW

10. Review of proposed facilities and practices:

The Chair provided an overview of the arrangement for the facilities and practices.

Point of Discussion:

1. An Institutional Representative confirmed that there are wall-mounted eyewash bottles larger than the 4-ounce size shown in the Photos. The Committee recommended that a photo of the wall-mounted eyewash bottles be provided to IBC Services.

11. Site requirements:

The Chair reviewed training and communication requirements for maintaining IBC approval with the Institutional Representatives.

12. Vote on the Site:

The Committee voted for the following determination on the Site:

X	APPROVED
	CONDITIONALLY APPROVED
	TABLED
	DISAPPROVED

DETERMINATION VOTE - YES: 3

NO: 0

ABSTAIN: 0

13. Advice to the Institution: None.

14. Meeting adjourned: The meeting was adjourned at 9:08 am Eastern Time.

15. Post-meeting notes: None.

Documents reviewed:

Agenda

Protocol, Version 0.0, dated 09-19-2025

Investigator's Brochure, Version 9.0, dated 02-25-2026

Investigational Medicinal Product Manual, Version 1.0, dated 02-19-2026

Biological Risk Assessment and Summary, updated 02-27-2026

Site Map, dated 02-03-2025

Site Inspection Checklist, expires 01-28-2027, updated 03-02-2026

Photos, dated 01-24-2025

Biohazard Sign, ADVM-022, dated 02-03-2025

SOP, Biosafety for ADVM-022, dated 03-02-2026

Training, Shipping Certifications, expire 2026, 2027

CV, Chaudhry, N., signed 12-16-2024